Looks like this event has already ended.
Check out upcoming events by this organizer, or organize your very own event.
Showcasing Entrepreneurship in the Life Sciences: A panel discussion and networking event
Tuesday, October 12, 2010 from 5:00 PM to 8:30 PM (EDT)
Showcasing Entrepreneurship in the Life Sciences:
A panel discussion and networking event
The University of Massachusetts Boston Venture Development Center and Propel Careers are proud to host a panel discussion and networking event intended to showcase life sciences entrepreneurship in MA. Come listen to current early stage entrepreneurs discuss their experiences, mingle with the next generation of entrepreneurs, and interact with industry professionals who are committed to helping ensure the success of early stage ventures in MA.
If you are a MA-based student interested in attending this event, financial assistance is available through the Stay in MA program. Please visit www.stayinma.com
Date: Tuesday, October 12, 2010
Time: 5:00 - 8:30pm
Location: University of Massachusetts Boston Venture Development Center, 100 Morrissey Blvd, Boston, MA 02125-3393
5:00pm-6:00pm – Registration and Open Networking
6:00pm-6:15pm – Introductions and Overview
- UMass Boston Venture Development Center
- Propel Careers
6:15 pm-7:15pm – Panel Discussion of Entrepreneurship
- Moderator: Susan Windham-Bannister, Ph,D, President and CEO Massachusetts Life Sciences Center
- Panelist: Bernadette C. Fendrock, President and CEO, Hepregen Corporation
- Panelist: Nader Yaghoubi, M.D., Ph.D., Partner, Dynamics Group, LLC
- Panelist: Susan Riley Keyes, PhD, JD, Director, Business Development, Nemucore Medical Innovations,Inc
- Panelist: Dustin Armstrong, Ph.D., Vice President Research, 4s3 Biosciences, Inc
- Panelist: Jason Rolland, Ph.D., Director of Research, Diagnostics for All
7:15pm-8:30pm – Open Networking
Susan Windham-Bannister, Ph,D, President and CEO Massachusetts Life Sciences Center
On May 28, 2008, Dr. Susan Windham-Bannister was appointed by the Massachusetts Life Sciences Center Board of Directors to be the Center’s first President and CEO. She officially assumed that position in July, 2008. Dr. Windham-Bannister is former Managing Vice President of the Commercial Strategy Group for Abt Bio-Pharma Solutions Inc. In that capacity, she managed a research-based consulting business that provides consulting services to firms in the life sciences -- health care delivery, pharmaceuticals, biotech, diagnostics, devices and healthcare information technology. Dr. Windham-Bannister was a member of Abt Bio-Pharma Solutions’ corporate management team, and a founding member of the commercial division of Abt Associates, the parent company. Dr. Windham-Bannister has 35 years of consulting experience in life sciences and has worked with companies that represent all major industry sectors. Dr. Windham-Bannister has co-authored two books: Competitive Strategy for Health Care Organizations and Medicaid and Other Experiments in State Health Policy. She also has written several articles on competition in today’s health care marketplace. Dr. Windham-Bannister holds a B.A. from Wellesley College, a doctorate in health policy and management from the Heller School at Brandeis University, and was a post-doctoral fellow at Harvard University’s John F. Kennedy School. She completed her doctoral work under a fellowship from the Ford Foundation.
Bernadette C. Fendrock, President and CEO, Hepregen Corporation
Ms. Fendrock is co-founder, president and CEO of Hepregen. Ms. Fendrock comes to Hepregen with more than twenty years of commercial experience in the life sciences industry. As vice president at Genzyme Corporation, Ms. Fendrock was responsible for the commercial planning and market launch of biosurgical products to treat post operative adhesions. Prior to Genzyme, Ms. Fendrock held positions as director of business development, Somatix, Inc., a start-up gene therapy company, and project manager, Genetics Institute (now Wyeth). Ms. Fendrock also has been a business consultant for the Harvard-MIT Division of Health Sciences and Technology and the Biomedical Enterprise Program (a collaboration with The Sloan School at MIT) and Acusphere, Inc. Ms. Fendrock holds a B.A. degree with a major in molecular biology from Wellesley College, a S.M. degree from MIT in interdisciplinary science and a M.B.A. from The Wharton School of the University of Pennsylvania.
Nader Yaghoubi, M.D., Ph.D., Partner, Dynamics Group, LLC
Dr. Nader Yaghoubi has over 10 years of experience in the creation, operations and financing of life science companies. Dr. Yaghoubi is currently a Partner at Dynamics Group, LLC, an investment firm focused on both public and later-stage private companies. Previously, he was Founder and President of DeNovo Bioworks, a company that worked with leading early-stage companies on Corporate Development and Startup Operations. Before starting DeNovo Bioworks, he was the first employee at BIND Biosciences and Selecta Biosciences, where he worked with the founders to launch the companies and rapidly get operational. Previously, he was at Zero Stage Capital, a venture capital firm where he was responsible for investing in the life sciences sector, and earlier did an internship at Advent International. Prior to this, he was a Health Care Entrepreneurship Fellow at Boston University, where he worked with scientists and physicians to develop new healthcare-related businesses. Before his fellowship, he was a surgical resident in the Department of Surgery at Lenox Hill Hospital in New York. Dr. Yaghoubi received an M.D. and Ph.D. in Molecular Pharmacology from the combined degree program at Boston University School of Medicine. His doctorate work on the development of high-throughput automated electrophysiological systems resulted in four issued patents, received one of the University's highest awards for dissertational research, and was the basis of a venture-backed biotechnology company that he co-founded.
Susan Riley Keyes, PhD, JD, Director, Business Development, Nemucore Medical Innovations, Inc
Dr. Keyes has over 25 years of experience in preclinical drug research and development, and business development in academia and industry. For the past 12 years, she negotiated licenses for a wide variety of life science technologies, with startups and with mid and large cap companies, both in the USA and internationally. Dr. Keyes is presently working as Director of Business Development for Nemucore Medical Innovations, a start up company developing treatments for ovarian cancer through targeting of therapeutics and conquering multi-drug resistance. Before a career in business development Dr. Keyes spent over 15 years developing therapeutic agents, primarily for cancer at Yale University, Dana-Farber Cancer Institute and Biomeasure Inc/Ipsen Pharmaceuticals. Therapeutic development includes agents that have reached phase III clinical trial or reached the market. Dr. Keyes holds a Ph.D. in Pharmacology from the University of Connecticut Health Center and a J.D. from Suffolk University, School of Law. Dr. Keyes volunteers with rare disease foundations, which includes serving on the Board of National Tay-Sacks and Allied Diseases and supporting the United Mitochondrial Disease Foundation. Currently, Dr. Keyes is serving on the Board of her professional society, AUTM, as the VP for the Eastern Region.
Dustin Armstrong, PhD, Vice President, Research, 4s3 Bioscience, Inc.
Dustin Armstrong co-founded 4s3 Bioscience in 2007 and leads the scientific development of the company’s preclinical therapeutic programs which are focused on treating orphan genetic disease. 4s3 raised seed-funding from Genzyme Ventures in 2008 and licensed an antibody-based technology with novel intracellular-delivery capabilities. As a primary investigator on behalf of 4s3, Dustin is utilizing NIH/R21 Exploratory grant support and patient foundation funding from the Muscular Dystrophy Association to generate and test novel product candidates for Myotonic Dystrophy and Myotubular Myopathy, two genetic muscle disorders with no current therapies. In addition to this grant funding, 4s3 was recently awarded a competitive accelerator loan from the State of Massachusetts Life Science Center which will enable 4s3 to further validate its technology and disease product candidates in highly predictive preclinical models of human disease. Prior to founding 4s3, Dustin joined Novartis as a postdoctoral fellow at the company’s Global Research & Development center in Cambridge, MA. In the Models of Disease group, Dustin’s research focused on epigenetic control and pharmacological activation of endogenous muscle stem cells. His independent research project resulted in successful intellectual property filings for the company and he was recognized through a Spot-award for “outstanding contributions achieved through above-and-beyond effort.” Dustin’s graduate work focused on Molecular Muscle Biology and he received his Ph.D. from the University of Illinois at Chicago. He earned his B.S. from Alma College in Alma, Michigan where he graduated Magna Cum Laude and was also selected 1st team Academic All-American, Team Captain, and MVP (Football).
Jason Rolland, PhD, Director of Research, Diagnostics For All
Dr. Rolland joined Diagnostics For All in 2010 as the Director of Research. He has a broad background in polymer chemistry and nanofabrication. He was formerly Director of Research and Development at Liquidia Technologies, a startup in RTP, NC which he co-founded in 2004. Dr. Rolland is a co-inventor of the PRINT® platform, a novel technique for the fabrication of engineered nanoparticles with controlled size, shape, and chemistry. His research was awarded the National Starch & Chemical Company Award for Outstanding Graduate Research in Polymer Chemistry (2007) and has been featured in Science magazine and Chemical and Engineering News. He has led numerous multi-disciplinary projects including the fabrication of solvent-compatible microfluidics for chemical synthesis, large-scale reel to reel fabrication of nanoparticles, and the development of novel vectors for siRNA delivery in collaboration with Abbott Laboratories. Dr. Rolland has a B.S. in Chemistry from Virginia Tech and a Ph.D. in Polymer Chemistry from the University of North Carolina at Chapel Hill.
When & Where
Propel Careers and University of Massachusetts Boston Venture Development Center